285 related articles for article (PubMed ID: 16157934)
1. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Whelan TJ; Goss PE; Ingle JN; Pater JL; Tu D; Pritchard K; Liu S; Shepherd LE; Palmer M; Robert NJ; Martino S; Muss HB
J Clin Oncol; 2005 Oct; 23(28):6931-40. PubMed ID: 16157934
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
3. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
4. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
5. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
6. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
[TBL] [Abstract][Full Text] [Related]
7. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
10. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Koeberle D; Thuerlimann B
Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
[TBL] [Abstract][Full Text] [Related]
11. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
12. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
16. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Moy B; Tu D; Pater JL; Ingle JN; Shepherd LE; Whelan TJ; Goss PE
Ann Oncol; 2006 Nov; 17(11):1637-43. PubMed ID: 16936184
[TBL] [Abstract][Full Text] [Related]
19. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Dixon JM; Renshaw L; Langridge C; Young OE; McHugh M; Williams L; Murray J; Macaskill EJ; McCaig F; Dixon OM; Fallowfield LJ
Breast Cancer Res Treat; 2011 Feb; 125(3):741-9. PubMed ID: 20821047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
